Wipfli Financial Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Wipfli Financial Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$0	Buy	+39	New	+$299	﹤0.01%	2550

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wipfli Financial Advisors's AVIR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Atea Pharmaceuticals (AVIR) in Q3 2022: 39 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2550 among its holdings.

126 funds tracked by Wall St. Rank hold AVIR as of Q3 2022.

Wipfli Financial Advisors held 39 shares of Atea Pharmaceuticals worth $0 as of Q3 2022.
Atea Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Atea Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2550 holding.
126 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.